Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Cerilliant
Teva
Mallinckrodt
Harvard Business School
US Department of Justice
Moodys
Merck
Fuji

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,656,935

« Back to Dashboard

Which drugs does patent 6,656,935 protect, and when does it expire?

Patent 6,656,935 protects STENDRA and is included in one NDA.

This patent has thirty-nine patent family members in twenty-five countries.
Summary for Patent: 6,656,935
Title: Aromatic nitrogen-containing 6-membered cyclic compounds
Abstract:An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I): ##STR1## wherein Ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group; R.sup.1 is a substituted or unsubstituted lower alkyl group, --NH--Q--R.sup.3 (R.sup.3 is a substituted or unsubstituted nitrogen containing heterocyclic group, and Q is a lower alkylene group or a single bond), or --NH--R.sup.4 (R.sup.4 is a substituted or unsubstituted cycloalkyl group); R.sup.2 is a substituted or unsubstituted aryl group; one of Y and Z is .dbd.CH--, and the other is .dbd.N--, or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent selective PDE V inhibitory activities, and hence, being useful in the prophylaxis or treatment of penile erectile dysfunction, etc.
Inventor(s): Yamada; Koichiro (Saitama-ken, JP), Matsuki; Kenji (Saitama-ken, JP), Omori; Kenji (Saitama, JP), Kikkawa; Kohei (Kawaguchi, JP)
Assignee: Tanabe Seiyaku Co., Ltd. (Osaka, JP)
Application Number:09/925,892
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,656,935
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,656,935

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-001 Apr 27, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF ERECTILE DYSFUNCTION ➤ Sign Up
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-002 Apr 27, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF ERECTILE DYSFUNCTION ➤ Sign Up
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-003 Apr 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF ERECTILE DYSFUNCTION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,656,935

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan11-261852Sep 16, 1999
Japan2000-130371Apr 28, 2000

Non-Orange Book US Patents Family Members for Patent 6,656,935

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,273,868 Pyrazine derivatives ➤ Sign Up
6,797,709 Aromatic nitrogen-containing 6-membered cyclic compounds ➤ Sign Up
7,220,736 Pyrimidine compounds ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Cantor Fitzgerald
Fuji
Mallinckrodt
McKesson
Argus Health
Boehringer Ingelheim
Johnson and Johnson
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.